Neue Suche | Kongressdetail
Druckansicht
 
 

First EASL NAFLD Summit: Diagnosis and pharmacotherapy of NASH

evvnt Platform / evvnt
Kongressthemen
NAFLD is the leading cause of chronic liver disease not only in Western countries but also among developing countries of the Far East, South Asia, the Middle East, and Latin America. In the US and Europe, nearly 40% of the population have NAFLD and approximately 20% of these individuals are likely to develop progressive liver disease (i.e. NASH) that lead to liver fibrosis and cirrhosis. Another emerging challenge is hepatocellular cancer which increasingly arises in precirrhotic stages.
Kongressorganizer (PCO)
European Association for the Study of the Liver (EASL)
Anmerkungen
Speakers: Prof. Ali Canbay (Germany), Prof. Claus Hellebrand (Germany), Prof. Wing-Kin Syn (United States), Prof. Michael Trauner (Austria)
 

Anfragen und Anmeldung:

https://go.evvnt.com/125207-1
Frau EASL The Home of Hepatology
41 022 807 0360
 
Kategorien
Allgemeinmedizin
Sprache
Englisch
Kongressgebühr
EASL Member (VAT exckusive): EUR 450 , Non Member (VAT exckusive): EUR 550 , Young Investigator and Nurse (EASL Member - VAT exckusive): EUR 150 , Young Investigator and Nurse (Non Member - VAT exckusive): EUR 200
Veranstalter Kontakt
83 Great Titchfield Street
W1W 6RH London
Großbritannien
Tel: +44 0207 3230 450
hello@evvnt.com
 
"GOING INTERNATIONAL fördert den Zugang zu Aus-, Fort- und Weiterbildung, unabhängig von sozialen, geographischen und nationalen Grenzen."

newTreeAGEM - Arbeitsgemeinschaft Ethnomedizin e. V.European Health Forum GasteinEuropean Public Health Association (EUPHA)Ärzte der WeltSwiss Tropical and Public Health InstituteAnästhesie in Entwicklungsländern e. V.Charité International Academy

Facebook

Sagen Sie uns Ihre professionelle Meinung

Zur Umfrage

Zur Umfrage